4-(4-bromobutoxy)-2-hydroxy-3-propylacetophenone | 92518-06-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(4-bromobutoxy)-2-hydroxy-3-propylacetophenone
• 英文别名: 2'-Hydroxy-3'-(n-propyl)-4'-(4-bromobutoxy)-acetophenone；1-[4-(4-Bromobutoxy)-2-hydroxy-3-propylphenyl]ethanone；4-(4-acetyl-3-hydroxy-2-propylphenoxy)-n-butyl bromide；4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl bromide
• CAS: 92518-06-4
• 化学式: C₁₅H₂₁BrO₃
• 分子量: 329.234
• InChiKey: VLDMVBPLPZYQKX-UHFFFAOYSA-N

物化性质

• 沸点：
  180 °C(Press: 0.25 Torr)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-bromobutoxy)-2-hydroxy-3-propylacetophenone 在 盐酸 作用下， 以 N-甲基乙酰胺 为溶剂， 生成 4-(4-cyanobutoxy)-2-hydroxy-3-propylacetophenone
  参考文献：
  名称：

  Leukotriene antagonists

  摘要：

  这项发明提供了新颖的烷烃衍生物，这些衍生物是白三烯拮抗剂，同时提供了这些衍生物的配方以及利用这些衍生物治疗由白三烯过度释放引起的疾病的方法。

  公开号：

  US04661505A1
• 作为产物：
  描述：

  2,4-二羟基-3-丙基苯乙酮 以79%的产率得到
  参考文献：
  名称：

  DEASON, JAMES R.;STEALEY, MICHAEL A.;WEIER, RICHARD M.

  摘要：

  DOI：

文献信息

• Leukotriene LTD.sub.4 and LTB.sub.4 antagonists
  申请人：G. D. Searle & Co.

  公开号：US04923891A1

  公开（公告）日：1990-05-08

  This invention encompasses compounds of Formula I ##STR1## and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein: X, Y, and Z are each independently O or S with S optionally oxidized to S=O; Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms; R.sub.1 is hydrogen or lower alkyl; n is 0 to 5; R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl. This invention is in the field of pharmaceutical agents which act as leukotriene D.sub.4 (LTD.sub.4) antagonists and includes embodiments which act as leukotriene B.sub.4 (LTD.sub.4) antagonists.

  这项发明涵盖了Formula I的化合物##STR1##及其药用可接受的盐和几何和光学异构体，其中：X、Y和Z分别独立地为O或S，其中S可氧化为S=O；Alk为含有1-6个碳原子的直链或支链烷基或羟基烷基；R.sub.1为氢或较低的烷基；n为0至5；R.sub.2为氢、较低的烷基、环烷基、--(CH.sub.2).sub.n --CO.sub.2 R.sub.1、苯基、苯基取代物与卤素、较低烷基或较低烷氧基；Ar为5,6,7,8-四氢-1-萘基、苯基或苯基取代物与较低烷基、羟基、较低烷氧基或较低烷酰基。这项发明涉及作为白三烯D.sub.4（LTD.sub.4）拮抗剂的药用剂，包括作为白三烯B.sub.4（LTD.sub.4）拮抗剂的实施形式。
• Derivatives of (Phenylsulfanyl)benzoic Acids with Multiple Antileukotrienic Activity
  作者：Miroslav Kuchař、Vojtěch Kmoníček、Vladimíra Panajotová、Antonín Jandera、Bohumila Brunová、Richard Junek、Věra Bucharová、Jan Čejka、Dalibor Šatinský

  DOI：10.1135/cccc20042098

  日期：——

  A series of derivatives of (phenylsulfanyl)benzoic acids bearing quinoline, 2,4-dihydroxy-3-propylacetophenone and 2,4-difluorobiphenyl moieties were prepared and their antileukotrienic activities evaluated. Some of the compounds were found to display multiple antileukotrienic effect in the inhibition of LTB₄biosynthesis, binding to LTD₄and LTB₄receptors, superior to the standards (zileuton and zafirlukast) used. The compounds had an antiinflammatory effect, manifested with quinoline derivatives by a significant inhibition of bronchospasm induced by LTD₄and/or albumin. The results of regression analysis correspond to the observation that the most active compounds belong to quinoline derivatives with the lowest lipophilicity. X-ray analysis of the quinoline compounds revealed that an intramolecular hydrophobic interaction of their aromatic rings does not occur in the solid state.

  一系列带有喹啉、2,4-二羟基-3-丙基苯乙酮和2,4-二氟联苯基团的(苯基硫基)苯甲酸衍生物已经制备，并评估了它们的抗白三烯活性。发现其中一些化合物在抑制LTB₄生物合成、结合到LTD₄和LTB₄受体方面显示出多重抗白三烯效应，优于所使用的标准物质（齐鲁通和扎非鲁卡斯特）。这些化合物具有抗炎作用，喹啉衍生物表现出通过显著抑制LTD₄和/或白蛋白诱导的支气管痉挛来体现。回归分析的结果与观察结果相符，即最活性的化合物属于脂溶性最低的喹啉衍生物。喹啉化合物的X射线分析显示，它们的芳香环之间不存在固态中的分子内疏水相互作用。
• Derivatives of hydroxyphenylsulfanylbenzoic and hydroxphenylsulfanylarylacetic acids
  申请人：Leciva, A.S.

  公开号：US06303612B1

  公开（公告）日：2001-10-16

  Processes for the preparation of derivatives of hydroxyphenylsulfanylbenzoic and hydroxyphenylsulfanylarylacetic acids of Formula (I) and pharmaceutical compositions including these compounds are provided: wherein X is H, halogen or NO2 group, n is 0 or 1, and m is 2 to 4 if Z is either 4-acetyl-3 -hydroxy-2-propylphenoxy of Formula (II): or a piperazinyl residue, or m is 1 if Z is quinolin-2-yl or 6-chloroquinoli-2-yl.

  提供了制备羟基苯硫基苯甲酸和羟基苯硫基芳基乙酸衍生物的过程以及包括这些化合物的药物组合物： 其中X为H、卤素或NO2基团，n为0或1，如果Z为4-乙酰基-3-羟基-2-丙基苯氧基的化合物（II）或哌嗪基残基，则m为2至4；如果Z为喹啉-2-基或6-氯喹啉-2-基，则m为1。
• 2,4-Dihydroxyacetophenone Derivatives as Antileukotrienics with a Multiple Activity Mechanism
  作者：Miroslav Kuchař、Kateřina Čulíková、Vladimíra Panajotovová、Bohumila Brunová、Antonín Jandera、Vojtěch Kmoníček

  DOI：10.1135/cccc19980103

  日期：——

  A series of 2,4-dihydroxy-3-propylacetophenone derivatives containing alkylthiobenzoic or arylacetic acid moiety was prepared. The antileukotrienic activity of the substances was assessed in terms of inhibition of the biosynthesis of LTB₄ and bonding to LTB₄ and LTD₄ receptors. Some of the substances were found to exert a complex antileukotrienic effect in all of the three tests. The compounds also displayed an antiinflammatory effect, as manifested by a significant inhibition of LTD₄-induced bronchospasm.

  一系列含有烷基硫代苯甲酸或芳基乙酸基团的2,4-二羟基-3-丙基乙酚衍生物已经制备。这些物质的抗白三烯活性以抑制LTB₄的生物合成和与LTB₄和LTD₄受体的结合来评估。发现其中一些物质在所有三项测试中产生复杂的抗白三烯效应。这些化合物还显示出抗炎作用，表现为明显抑制LTD₄诱导的支气管痉挛。
• Thiadiazole compounds as antagonists of SRS-A
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04855310A1

  公开（公告）日：1989-08-08

  Novel heterocyclic compounds shown by the general formula ##STR1## or the pharmaceutically acceptable salts thereof useful as medicament in particular as antagonist of slow reacting substance of anaphylaxis (SRS-A).

  新颖的杂环化合物，其一般公式为##STR1##或其药学上可接受的盐，可用作药物，特别是作为过敏性反应缓慢物质（SRS-A）的拮抗剂。